BillionToOne, Inc. — Investor Relations & Filings

BillionToOne is a precision diagnostics company focused on advancing disease detection through molecular diagnostics. They utilize a proprietary genetic testing platform, powered by Quantitative Counting Templates (QCTs™) and single-molecule Next-Generation Sequencing (smNGS), to directly measure sparse disease-causing DNA fragments at the single base-pair level. This technology quantifies minute variations using cell-free DNA, enhancing diagnostic accuracy and efficiency. Their core applications include non-invasive prenatal screening, exemplified by the UNITY test, and liquid biopsy for oncology, which aids in identifying cancer treatment options and enabling earlier tumor tracking. The company's mission is to make molecular diagnostics more accurate, efficient, and accessible.